TerryJaySmithMD

Diabetes, Lipid Metabolism

Professor, Ophthalmology & Visual Sciences, University of Michigan Medical School

Dr. Smith is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Terry Smith is an endocrinologist who sees patients at the University of Michigan Kellogg Eye Center in Ann Arbor. His clinical specialties include Graves' disease, thyroid-associated ophthalmopathy, and metabolic diseases.

Dr. Smith is the Frederick G.L. Huetwell Professor of Ophthalmology and Visual Sciences and also serves as Professor of Internal Medicine at the U-M Medical School. His research focuses on autoimmune thyroid disease, extracellular matrix, cell signaling, gene expression, ecosanoids, inflammation, and cytokine action.

To make an appointment, please call Kellogg’s Thyroid Eye Disease Clinic at 734-764-5106. To refer a patient, please visit www.kellogg.umich.edu/refer.

University of ChicagoFellowship, Endocrinology, Diabetes, and Metabolism, 1979 - 1981
Sinai Hospital of BaltimoreResidency, Internal Medicine, 1976 - 1977
University of Illinois College of Medicine at ChicagoInternship, Internal Medicine, 1975 - 1976
University of Missouri-Columbia School of MedicineClass of 1975

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

PubMed

TSHR-IGF-IR complex drives orbital fibroblast misbehavior in thyroid eye disease.
Terry J Smith
Current Opinion in Endocrinology, Diabetes, and Obesity. 2024-10-01
1 citations
Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials.
Terry J Smith, Dustin Cavida, Kate Hsu, Sun Kim, Qianhong Fu
Ophthalmology. 2024-07-01
Hearing abnormalities in patients treated with teprotumumab.
Jason A Brant, Don O Kikkawa, Terry J Smith
Nature Reviews. Endocrinology. 2024-07-01

Journal Articles

The Insulin-like Growth Factor-I Receptor and Its Role in Thyroid-Associated Ophthalmopathy
Terry Smith, MD, Nature
HIF2A-LOX Pathway Promotes Fibrotic Tissue Remodeling in Thyroid-Associated Orbitopathy
Terry J Smith, Alon Kahana, Endocrinology
Orbital Fibroblasts from Patients with Thyroid-Associated Ophthalmopathy Modulate TNF-Α Expression in CD34
Terry Smith, MD, Investigative Ophthalmology and Visual Science

Lectures

Teprotumumab for Thyroid-Associated Opthalmopathy
ENDO 2018: 100th Endocrine Society Annual Meeting - Chicago, Illinios - 03/20/2018

Clinical Challenges: Long-Term Management of Thyroid Eye DiseaseOctober 14th, 2022
Clinical Challenges: Settling on the Optimal Treatment for Thyroid Eye DiseaseSeptember 15th, 2022
Clinical Challenges: Knowing When It's Thyroid Eye DiseaseAugust 15th, 2022
Join now to see all

Immunoglobulin Activation Of FibroblastsNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
Functional Diversity Of Orbital FibroblastsNational Eye Institute2009–2011
Regulation Of Retroocular Connective TissueNational Eye Institute2008–2011
Regulation Of Retroocular Connective Tissue: Interleukin IL-16 Levels In PatiNational Center For Research Resources2005–2010
Immunoglobulin Activation Of FibroblastsNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2008
Regulation Of Retroocular Connective TissueNational Eye Institute2000–2008
Functional Diversity Of Orbital FibroblastsNational Eye Institute1999–2008
Regulation Of Retroocular Connective Tissue: Interleukin IL-16 Levels In Pati...National Center For Research Resources2004
Functional Diversity Of Orbital FibroblastsNational Eye Institute1997–1999
Regulation Of Retroocular Connective TissueNational Eye Institute1994–1999
Regulation Of Retro-Ocular Connective TissueNational Eye Institute1993